恩华药业：NH160030片获批开展临床试验

Core Viewpoint - Enhua Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of its new opioid analgesic, NH160030, which is a next-generation oral µ-opioid receptor agonist [1] Group 1 - The company announced on November 12 that it has obtained the clinical trial approval notice for NH160030 in four specifications [1] - NH160030 is designed as an oral medication, indicating its potential for ease of use in pain management [1] - The clinical trials for NH160030 are set to commence shortly, marking a significant step in the drug development process [1]